DLF Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 28, 2025, 1:49 pm

Competitors of DLF Ltd

All Competitor Stocks of DLF Ltd

Quarterly Result

Last Updated: August 20, 2025, 11:30 am

Below is a detailed analysis of the quarterly data for DLF Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 2,717.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,128.00 Cr. (Mar 2025) to 2,717.00 Cr., marking a decrease of 411.00 Cr..
• For Expenses, as of Jun 2025, the value is 2,353.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,150.00 Cr. (Mar 2025) to 2,353.00 Cr., marking an increase of 203.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 364.00 Cr.. The value appears to be declining and may need further review. It has decreased from 978.00 Cr. (Mar 2025) to 364.00 Cr., marking a decrease of 614.00 Cr..
• For OPM %, as of Jun 2025, the value is 13.00%. The value appears to be declining and may need further review. It has decreased from 31.00% (Mar 2025) to 13.00%, marking a decrease of 18.00%.
• For Other Income, as of Jun 2025, the value is 264.00 Cr.. The value appears strong and on an upward trend. It has increased from 220.00 Cr. (Mar 2025) to 264.00 Cr., marking an increase of 44.00 Cr..
• For Interest, as of Jun 2025, the value is 79.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 109.00 Cr. (Mar 2025) to 79.00 Cr., marking a decrease of 30.00 Cr..
• For Depreciation, as of Jun 2025, the value is 34.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 37.00 Cr. (Mar 2025) to 34.00 Cr., marking a decrease of 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 515.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,053.00 Cr. (Mar 2025) to 515.00 Cr., marking a decrease of 538.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Mar 2025) to 26.00%, marking an increase of 9.00%.
• For Net Profit, as of Jun 2025, the value is 763.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,282.00 Cr. (Mar 2025) to 763.00 Cr., marking a decrease of 519.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.08. The value appears to be declining and may need further review. It has decreased from 5.18 (Mar 2025) to 3.08, marking a decrease of 2.10.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:26 am

Growth

Last Updated: September 5, 2025, 3:05 am

Balance Sheet

Last Updated: July 25, 2025, 3:19 pm

Below is a detailed analysis of the balance sheet data for DLF Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 495.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 495.00 Cr..
• For Reserves, as of Mar 2025, the value is 42,055.00 Cr.. The value appears strong and on an upward trend. It has increased from 38,936.00 Cr. (Mar 2024) to 42,055.00 Cr., marking an increase of 3,119.00 Cr..
• For Borrowings, as of Mar 2025, the value is 4,103.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4,834.00 Cr. (Mar 2024) to 4,103.00 Cr., marking a decrease of 731.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 21,819.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,804.00 Cr. (Mar 2024) to 21,819.00 Cr., marking an increase of 7,015.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 68,472.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 59,069.00 Cr. (Mar 2024) to 68,472.00 Cr., marking an increase of 9,403.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 3,502.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,880.00 Cr. (Mar 2024) to 3,502.00 Cr., marking a decrease of 378.00 Cr..
• For CWIP, as of Mar 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 71.00 Cr. (Mar 2024) to 86.00 Cr., marking an increase of 15.00 Cr..
• For Investments, as of Mar 2025, the value is 21,336.00 Cr.. The value appears strong and on an upward trend. It has increased from 20,138.00 Cr. (Mar 2024) to 21,336.00 Cr., marking an increase of 1,198.00 Cr..
• For Other Assets, as of Mar 2025, the value is 43,549.00 Cr.. The value appears strong and on an upward trend. It has increased from 34,981.00 Cr. (Mar 2024) to 43,549.00 Cr., marking an increase of 8,568.00 Cr..
• For Total Assets, as of Mar 2025, the value is 68,472.00 Cr.. The value appears strong and on an upward trend. It has increased from 59,069.00 Cr. (Mar 2024) to 68,472.00 Cr., marking an increase of 9,403.00 Cr..

Notably, the Reserves (42,055.00 Cr.) exceed the Borrowings (4,103.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for DLF Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 17.64. This value is within the healthy range. It has increased from 11.02 (Mar 24) to 17.64, marking an increase of 6.62.
• For Diluted EPS (Rs.), as of Mar 25, the value is 17.64. This value is within the healthy range. It has increased from 11.02 (Mar 24) to 17.64, marking an increase of 6.62.
• For Cash EPS (Rs.), as of Mar 25, the value is 11.49. This value is within the healthy range. It has increased from 7.18 (Mar 24) to 11.49, marking an increase of 4.31.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 171.90. It has increased from 159.30 (Mar 24) to 171.90, marking an increase of 12.60.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 171.90. It has increased from 159.30 (Mar 24) to 171.90, marking an increase of 12.60.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 32.29. It has increased from 25.96 (Mar 24) to 32.29, marking an increase of 6.33.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 12.57. This value is within the healthy range. It has increased from 10.73 (Mar 24) to 12.57, marking an increase of 1.84.
• For PBIT / Share (Rs.), as of Mar 25, the value is 11.96. This value is within the healthy range. It has increased from 10.13 (Mar 24) to 11.96, marking an increase of 1.83.
• For PBT / Share (Rs.), as of Mar 25, the value is 9.13. This value is within the healthy range. It has increased from 8.69 (Mar 24) to 9.13, marking an increase of 0.44.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 10.89. This value is within the healthy range. It has increased from 6.59 (Mar 24) to 10.89, marking an increase of 4.30.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.64. This value is within the healthy range. It has increased from 11.02 (Mar 24) to 17.64, marking an increase of 6.62.
• For PBDIT Margin (%), as of Mar 25, the value is 38.91. This value is within the healthy range. It has decreased from 41.30 (Mar 24) to 38.91, marking a decrease of 2.39.
• For PBIT Margin (%), as of Mar 25, the value is 37.03. This value exceeds the healthy maximum of 20. It has decreased from 39.00 (Mar 24) to 37.03, marking a decrease of 1.97.
• For PBT Margin (%), as of Mar 25, the value is 28.28. This value is within the healthy range. It has decreased from 33.46 (Mar 24) to 28.28, marking a decrease of 5.18.
• For Net Profit Margin (%), as of Mar 25, the value is 33.70. This value exceeds the healthy maximum of 10. It has increased from 25.36 (Mar 24) to 33.70, marking an increase of 8.34.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 54.63. This value exceeds the healthy maximum of 20. It has increased from 42.43 (Mar 24) to 54.63, marking an increase of 12.20.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.26. This value is below the healthy minimum of 15. It has increased from 6.91 (Mar 24) to 10.26, marking an increase of 3.35.
• For Return on Capital Employeed (%), as of Mar 25, the value is 6.26. This value is below the healthy minimum of 10. It has increased from 5.43 (Mar 24) to 6.26, marking an increase of 0.83.
• For Return On Assets (%), as of Mar 25, the value is 6.28. This value is within the healthy range. It has increased from 4.52 (Mar 24) to 6.28, marking an increase of 1.76.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.11 (Mar 24) to 0.09, marking a decrease of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.12. It has increased from 0.11 (Mar 24) to 0.12, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 1.85. This value is within the healthy range. It has decreased from 2.30 (Mar 24) to 1.85, marking a decrease of 0.45.
• For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 0.80 (Mar 24) to 0.74, marking a decrease of 0.06.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 4. It has increased from 0.31 (Mar 24) to 0.34, marking an increase of 0.03.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 28.33. This value is within the healthy range. It has decreased from 36.30 (Mar 24) to 28.33, marking a decrease of 7.97.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 27.39. This value is within the healthy range. It has decreased from 34.43 (Mar 24) to 27.39, marking a decrease of 7.04.
• For Earning Retention Ratio (%), as of Mar 25, the value is 71.67. This value exceeds the healthy maximum of 70. It has increased from 63.70 (Mar 24) to 71.67, marking an increase of 7.97.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 72.61. This value exceeds the healthy maximum of 70. It has increased from 65.57 (Mar 24) to 72.61, marking an increase of 7.04.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 7.45 (Mar 24) to 7.83, marking an increase of 0.38.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.55. This value is within the healthy range. It has increased from 5.57 (Mar 24) to 8.55, marking an increase of 2.98.
• For Enterprise Value (Cr.), as of Mar 25, the value is 167,960.89. It has decreased from 222,572.40 (Mar 24) to 167,960.89, marking a decrease of 54,611.51.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 21.01. This value exceeds the healthy maximum of 3. It has decreased from 34.63 (Mar 24) to 21.01, marking a decrease of 13.62.
• For EV / EBITDA (X), as of Mar 25, the value is 53.99. This value exceeds the healthy maximum of 15. It has decreased from 83.83 (Mar 24) to 53.99, marking a decrease of 29.84.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 21.07. This value exceeds the healthy maximum of 3. It has decreased from 34.60 (Mar 24) to 21.07, marking a decrease of 13.53.
• For Retention Ratios (%), as of Mar 25, the value is 71.66. This value exceeds the healthy maximum of 70. It has increased from 63.69 (Mar 24) to 71.66, marking an increase of 7.97.
• For Price / BV (X), as of Mar 25, the value is 3.96. This value exceeds the healthy maximum of 3. It has decreased from 5.64 (Mar 24) to 3.96, marking a decrease of 1.68.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 21.07. This value exceeds the healthy maximum of 3. It has decreased from 34.60 (Mar 24) to 21.07, marking a decrease of 13.53.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness